0000905148-24-000849.txt : 20240301 0000905148-24-000849.hdr.sgml : 20240301 20240301191520 ACCESSION NUMBER: 0000905148-24-000849 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240228 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RODRIGUEZ RAUL R CENTRAL INDEX KEY: 0001190279 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29889 FILM NUMBER: 24712310 MAIL ADDRESS: STREET 1: 1180 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RIGEL PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001034842 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943248524 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-624-1100 MAIL ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-02-28 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001190279 RODRIGUEZ RAUL R RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true true CEO, President false Employee Stock Option (right to buy) 1.87 2024-02-28 4 A 0 300000 0 A 2033-01-26 Common Stock 300000 300000 D Employee Stock Option (right to buy) 1.27 2024-02-28 4 A 0 300000 0 A 2034-01-23 Common Stock 300000 300000 D The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. /s/ Raymond Furey (Attorney-in-Fact) 2024-03-01